Christopher Herbert

Bristol, ENG, GB 
Bristol, ENG, GB 

Overview

Christopher Herbert practices practicing medicine in Bristol, United Kingdom.

His clinical expertise encompasses Melanoma, Muir-Torre Syndrome, COVID-19, and Glioblastoma.

He is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Bristol, ENG, United Kingdom
Other Locations
Westburn Road, Aberdeen, SCT AB252ZN, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Enrollment Status: Completed
Publish Date: June 03, 2024
A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: December 20, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: December 20, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma
A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma
Enrollment Status: Completed
Publish Date: February 05, 2018
Intervention Type: Drug, Procedure, Genetic, Other
Study Phase: Phase 1
View 3 Less Clinical Trials

12 Total Publications

Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM Trial.
Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM Trial.
Journal: International journal of radiation oncology, biology, physics
Published: October 18, 2023

Frequently Asked Questions about Christopher Herbert

Is Christopher Herbert a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Christopher Herbert is classified as an Experienced expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Christopher Herbert participate in research or clinical trials?

Yes. Christopher Herbert has published 12 articles and abstracts on conditions like Melanoma. You can view a list of Christopher Herbert's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Herbert's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile